US biotechnology company buys Turkish generics drug maker

Istanbul, 25 April 2012 - Amgen, the US biotechnology company, is to acquire over 95% of Mustafa Nevzat Ilac a Turkish generic drug manufacturer. The acquisition worth about 700 million USD will increase Mustafa Nevzat’s presence in the emerging markets in the region and Africa. Commenting, Bob Bradway, Amgen’s Chief Operating Officer said, "Together with Mustafa Nevzat staff and management team, we plan to grow our business with high quality and innovative medicines in Turkey and the surrounding region”. Mustafa Nevzat is one of the oldest pharmaceutical companies in Turkey. Source: Invest in Turkey


© Copyright 2018 - Spot Blue International Property Ltd (4864440) - All Rights Reserved
envelopephone-handsetmap-marker linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram